Kenvue Inc. (NYSE:KVUE) Position Increased by Kiley Juergens Wealth Management LLC

Kiley Juergens Wealth Management LLC increased its stake in Kenvue Inc. (NYSE:KVUE) by 18.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,586 shares of the company’s stock after purchasing an additional 4,252 shares during the period. Kiley Juergens Wealth Management LLC’s holdings in Kenvue were worth $594,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the business. Clearstead Advisors LLC acquired a new position in shares of Kenvue during the 3rd quarter valued at $25,000. Planned Solutions Inc. acquired a new position in shares of Kenvue during the 4th quarter valued at $27,000. EverSource Wealth Advisors LLC acquired a new position in shares of Kenvue during the 3rd quarter valued at $28,000. AdvisorNet Financial Inc acquired a new position in shares of Kenvue during the 3rd quarter valued at $28,000. Finally, Global Retirement Partners LLC acquired a new position in shares of Kenvue during the 3rd quarter valued at $28,000. Institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

KVUE traded down $0.02 during trading on Tuesday, reaching $19.11. 20,306,557 shares of the stock traded hands, compared to its average volume of 16,870,912. Kenvue Inc. has a fifty-two week low of $17.82 and a fifty-two week high of $27.80. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78. The stock’s 50-day simple moving average is $19.88 and its two-hundred day simple moving average is $20.18.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The business had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.78 billion. The business’s quarterly revenue was down 2.7% compared to the same quarter last year. Equities research analysts anticipate that Kenvue Inc. will post 1.17 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Wednesday, February 14th were paid a dividend of $0.20 per share. The ex-dividend date was Tuesday, February 13th. This represents a $0.80 annualized dividend and a yield of 4.19%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on KVUE shares. William Blair started coverage on Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating on the stock. JPMorgan Chase & Co. decreased their target price on Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. Royal Bank of Canada decreased their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a report on Friday, February 9th. UBS Group lifted their target price on Kenvue from $20.00 to $23.00 and gave the stock a “neutral” rating in a report on Tuesday, December 19th. Finally, Sanford C. Bernstein started coverage on Kenvue in a report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $24.85.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.